Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Mon, Jul 6, 2026

1 updates

5:09 PM

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

nuvationbio.com

Mon, Jun 29, 2026

1 updates

8:00 AM

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

nuvationbio.com

Thu, Jun 25, 2026

2 updates

11:58 PM

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

nuvationbio.com

7:00 AM

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

nuvationbio.com

Wed, May 27, 2026

2 updates

4:05 PM

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

nuvationbio.com

8:00 AM

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

nuvationbio.com

Wed, May 13, 2026

1 updates

4:05 PM

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

nuvationbio.com

Wed, May 6, 2026

1 updates

8:00 AM

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

nuvationbio.com

Tue, May 5, 2026

1 updates

4:05 PM

Nuvation Bio to Participate in Upcoming Investor Conferences

nuvationbio.com

Mon, May 4, 2026

1 updates

4:10 PM

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

nuvationbio.com

Mon, Apr 27, 2026

1 updates

8:00 AM

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

nuvationbio.com

Tue, Apr 21, 2026

1 updates

6:00 PM

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Presentation / Abstractnuvationbio.com

Mon, Apr 20, 2026

1 updates

4:05 PM

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

nuvationbio.com